Alia Therapeutics, the first Italian genome editing company, was incorporated in late 2018 as a spin off of the University of Trento and is currently incubated in its biotech department. At the beginning of 2019, Alia secured a 1.35 million euros seed round led by BiovelocITA, the first Italian accelerator dedicated to biotech and co-founded by Sofinnova Partners.
Leveraging on its proprietary improved technology, Alia Therapeutics is developing new approaches to treat incurable genetic diseases. Its unique CRISPR-based genome editing tools allow unprecedented specificity in modifying the genome, which is particularly suited for the allele-specific elimination of dominant negative mutations. Alia is also developing new strategies to allow the in vivo traceless delivery of CRISPR nucleases. Alia Therapeutics' editing platform overcomes relevant limitations in genome editing technology, speeding up the development of genetic medicines.